Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on Thursday, April 15, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the fourth quarter and full year 2020 as well as provide a business update. The company’s press release concerning its fourth quarter 2020 financial results will be available after 1 p.m. Pacific Time on April 15, 2021, on its website at www.adamispharmaceuticals.com, and the company also expects to file its annual report on Form 10-K for year ended December 31, 2020 on that date.

Event: Adamis Fourth Quarter and Full Year 2020 Financial Results Conference CallDate: Thursday, April 15, 2021Time: 2 p.m. PT (5 p.m. ET)U.S. Dial-in (Toll Free): 1-877-423-9813TOLL/International Dial-in: 1-201-689-8573Conference ID: 13718220

Dennis J. Carlo, Ph.D., President and CEO of Adamis, will host the call along with other members of the management team. The call is open to the public and will provide an update on recent developments, events that have taken place during the quarter and certain target milestones and goals for future periods. Forward-looking statements concerning expectations regarding future company performance may be made during the conference call.

A live audio webcast of the conference call will also be available via this link – http://public.viavid.com/index.php?id=144486, with a replay available shortly after the live event.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis’ naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose, is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company’s subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com.  

Contact:

Adamis Investor Relations Robert UhlManaging DirectorWestwicke [e-mail]